LUMINA: A Phase III, Multicenter, Sham-Controlled, Randomized, Double-Masked Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 ug DE-109 for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye.
Phase of Trial: Phase III
Latest Information Update: 23 Nov 2019
Price : $35 *
At a glance
- Drugs Sirolimus (Primary)
- Indications Uveitis
- Focus Therapeutic Use
- Acronyms LUMINA
- Sponsors Santen Inc
- 22 Aug 2019 Planned End Date changed from 17 Apr 2021 to 30 Jun 2022.
- 22 Aug 2019 Planned primary completion date changed from 18 Feb 2021 to 30 Jun 2022.
- 19 Dec 2018 Status changed from not yet recruiting to recruiting.